← Back to screener

ImmunityBio, Inc. IBRX

Rank #2006 · Nasdaq · $8.7B market cap
⚠ Going-concern flag — the auditor (Deloitte & Touche LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
36.5
P/E
-14.9
P/B
-17.75
ROE
119.2%
Op. Margin
-58239.5%
Debt Ratio
-178%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -14.9x, P/B -17.75x. Ranks in the top 90% of the universe.

Profitability ★★☆☆☆
Average

ROE 119.2%. Ranks in the top 52% of the universe.

Safety ★★★★★
Excellent

Debt ratio -178%. Ranks in the top 5% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 159.2% year over year. Ranks in the top 2% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2015$0.0B–$-0.0B$0.4B––
2016$0.0B$-0.0B$-0.0B$-0.0B-869.7-289
2017$0.0B$-0.2B$-0.2B$0.1B-101218.642
2018$0.0B$-0.1B$-0.1B$0.4B-282954.59
2019$0.0B$-0.1B$-0.1B$0.3B-220266.712
2020$0.0B$-0.1B$-0.1B$0.2B-209338.310
2021$0.0B$-0.2B$-0.2B$-0.1B-7095.9-284
2022$0.0B$-0.2B$-0.2B$-0.2B-36509.1-294
2023$0.0B$-0.3B$-0.3B$-0.4B-35361.9-182
2024$0.0B$-0.4B$-0.4B$-0.6B-146374.2-186
2025$0.0B$-0.4B$-0.6B$-0.5B-58239.5-178

← See the full screener